Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Aelis Farma SA (AELIS) Stock Price & Analysis

3 Followers

AELIS Stock Chart & Stats

€0.88€0.01(1.63%)
At close: 5:30 PM GMT+1
€0.75€1Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
EUR 0.87 - EUR 0.88
52-Week Range
EUR 0.61 - EUR 2.30
Previous Close
EUR 0.86
Volume
N/A
Average Volume (3M)
26.58K
Market Cap
EUR 11.80M
Enterprise Value
EUR 10.79M
Total Cash (Recent Filing)
EUR 6.62M
Total Debt (Recent Filing)
EUR 4.38M
Price to Earnings (P/E)
―
Beta
0.80
Next Earnings
Apr 05, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Endocannabinoid Therapeutic Focus

A focused small-molecule platform targeting the endocannabinoid system gives Aelis Farma a defined scientific identity and potential to build expertise across related neurological and peripheral indications. This specialization can support durable pipeline development if clinical outcomes validate the approach.

Lead Program Differentiation

The lead program addresses a specific unmet-treatment objective through a differentiated mechanism: reducing THC psychoactivity without broadly disrupting normal endocannabinoid signaling. If successful, this design could support meaningful clinical differentiation and provide a clear basis for future product development.

Improving Operating Cash Flow

Although operating cash flow remained negative, the materially smaller outflow in 2025 indicates some improvement in cash consumption relative to the prior year. Sustaining or extending this trend would reduce the pace of funding needs and provide greater flexibility while development programs advance.

Bears Say

Declining Revenue Base

Recent revenue contraction weakens the company’s ability to support its operating structure through internally generated income. Revenue remaining well below 2023 levels also indicates that the business has not established a stable commercial trajectory, increasing reliance on future development success or external financing.

Persistent Losses And Negative Margins

Multi-year losses and deeply negative margins show that current revenue does not cover the company’s cost base. The deterioration to an approximately -309% net margin in 2025 underscores weak earnings quality and leaves profitability dependent on a substantial improvement in revenue, costs, or product development outcomes.

Cash Burn And Financing Risk

Persistent operating and free-cash-flow deficits require continued funding to sustain operations and clinical development. The simultaneous decline in equity reduces the capital cushion, increasing the risk that future financing or recapitalization could be needed and may constrain strategic flexibility through dilution pressure.

Aelis Farma SA News

AELIS FAQ

What was Aelis Farma SA’s price range in the past 12 months?
Aelis Farma SA lowest stock price was €0.61 and its highest was €2.30 in the past 12 months.
What is Aelis Farma SA’s market cap?
Aelis Farma SA’s market cap is €11.80M.
When is Aelis Farma SA’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Aelis Farma SA’s earnings last quarter?
Aelis Farma SA released its earnings results on Sep 15, 2026. The company reported -€0.176 earnings per share for the quarter.
Is Aelis Farma SA overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Aelis Farma SA pay dividends?
Aelis Farma SA does not currently pay dividends.
What is Aelis Farma SA’s EPS estimate?
Aelis Farma SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aelis Farma SA have?
Aelis Farma SA has 13,706,586 shares outstanding.
What happened to Aelis Farma SA’s price movement after its last earnings report?
Aelis Farma SA reported an EPS of -€0.176 in its last earnings report. Following the earnings report the stock price went up 1.053%.
Which hedge fund is a major shareholder of Aelis Farma SA?
Currently, no hedge funds are holding shares in FR:AELIS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology